AVTX
Avalo Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
19.83
▲ 0.01 (0.05%)
MARKET · —
Price
Open
19.26
Prev close
19.82
Day high
20.19
Day low
19.58
Volume
567.36K
Market cap
$1.06B
P/E (TTM)
—
52W range
8.65 – 24.27
Trailing performance
Returnvs SPY
1W
+1.23%
+2.6%
1M
+11.66%
+7.9%
3M
+19.46%
+16.4%
6M
+39.55%
+28.5%
YTD
+9.20%
-3.1%
1Y
+115.08%
+95.1%
3Y
-35.45%
-109.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.06B
Enterprise value$663.45M
Revenue (TTM)$59.00K
Gross profit$-47.89M
EBITDA$-91.25M
Net income$-100.33M
EPS (TTM)$-4.41
Free cash flow$-23.27M
Total cash$400.28M
Total debt$242.00K
Book value / share$8.48
Shares outstanding53.63M
Float40.15M
Short % of float24.52%
Dividend yield—
Beta (5Y)0.79
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.53
PEG ratio—
Price / sales—
Price / book2.34
EV / revenue11,244.89
EV / EBITDA-7.27
Gross margin0.00%
Operating margin-154847.45%
Profit margin0.00%
Return on equity-36.27%
Return on assets-18.50%
Debt / equity0.05
Current ratio19.31
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $59.00K | $441.00K | $1.92M | $18.05M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$78.26M | -$35.13M | -$31.54M | -$41.66M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$78.26M | -$35.13M | -$31.54M | -$41.66M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.62 | -0.83 | -34.5% |
| Mar 2026 | -1.07 | -0.98 | +8.6% |
| Dec 2025 | -1.50 | -0.37 | +75.3% |
| Sep 2025 | -1.64 | -2.19 | -33.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.50 | 9 | $0 | 0.0% |
| Next quarter | -0.48 | 9 | $0 | -100.0% |
| Current year | -2.55 | 9 | $0 | -100.0% |
| Next year | -2.63 | 10 | $0 | 0.0% |
Analyst targets & ownership
Mean target$44.15
High target$60.00
Low target$30.00
Implied upside122.66%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy2 / 13
Hold0
Sell / Strong sell0 / 0
Held by insiders1.69%
Held by institutions133.34%
Institutions holding170
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+307.43K
Net buying
Buy transactions
27
710.35K shares
Sell transactions
19
402.93K shares
Net transactions
+46
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
905.81K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | SULLIVAN CHRISTOPHER RYAN Chief Financial Officer |
SELL | 72.72K | $1.45M | Direct |
| Aug 18, 26 | SULLIVAN CHRISTOPHER RYAN Chief Financial Officer |
CONVERSION | 71.85K | $709.90K | Direct |
| Aug 17, 26 | DOYLE MITTIE Officer |
SELL | 1.00K | $20.00K | Direct |
| Aug 17, 26 | DOYLE MITTIE Officer |
CONVERSION | 1.00K | $12.65K | Direct |
| Aug 11, 26 | RILEY JENNIFER Officer |
SELL | 2.65K | $52.01K | Direct |
| Aug 10, 26 | DOYLE MITTIE Officer |
SELL | 679 | $13.58K | Direct |
| Aug 10, 26 | DOYLE MITTIE Officer |
CONVERSION | 679 | $5.46K | Direct |
| Jul 27, 26 | DOYLE MITTIE Officer |
SELL | 1.00K | $20.00K | Direct |
| Jul 27, 26 | DOYLE MITTIE Officer |
CONVERSION | 1.00K | $12.65K | Direct |
| Jun 30, 26 | DOYLE MITTIE Officer |
SELL | 4.65K | $93.08K | Direct |
| Jun 30, 26 | DOYLE MITTIE Officer |
CONVERSION | 4.65K | $50.67K | Direct |
| Jun 23, 26 | DOYLE MITTIE Officer |
SELL | 1.45K | $26.10K | Direct |
| Jun 23, 26 | DOYLE MITTIE Officer |
CONVERSION | 1.45K | $11.66K | Direct |
| May 28, 26 | DOYLE MITTIE Officer |
SELL | 679 | $10.86K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALMENOFF JUNE SHERIE |
Director | 4.17K | Conversion of Exercise of derivative security |
DOYLE MITTIE |
Officer | 51.78K | Sale |
GOLDMAN JONATHAN |
Director | 3.17K | Conversion of Exercise of derivative security |
KANTOFF AARON |
Director | 6.33K | Conversion of Exercise of derivative security |
KAPLAN GILLA |
Director | 6.33K | Conversion of Exercise of derivative security |
NEIL GARRY A. M.D. |
Chief Executive Officer | 190.31K | Stock Award(Grant) |
RILEY JENNIFER |
Officer | 37.04K | Sale |
SULLIVAN CHRISTOPHER RYAN |
Chief Financial Officer | 39.90K | Sale |
TRUEX SAMANTHA |
Director | 6.33K | Conversion of Exercise of derivative security |
VARKI PAUL C. J.D. |
Officer | 27.93K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
19.79
+0.21% from price
SMA 20
19.30
+2.75% from price
SMA 50
18.37
+7.92% from price
SMA 100
16.99
+16.70% from price
SMA 200
16.72
+18.58% from price
EMA 12
19.63
+1.00% from price
EMA 26
19.16
+3.48% from price
EMA 50
18.46
+7.39% from price
RSI (14)
55.3
Neutral
MACD (12,26,9)
0.47
Hist 0.04
ATR (14)
1.10
5.55% of price
Realised vol 30D
56.2%
Annualised
Bollinger upper
20.61
20, 2σ
Bollinger lower
17.99
20, 2σ
50 / 200 cross
Golden
18.37 vs 16.72
Trend bias
Above 200
+18.58%
Risk profile
Beta vs SPY
1.26
More volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
56.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-44.3%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
1.10
5.55% of price
Beta (reported)
0.79
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.30
Call-heavy session
Put / call open interest
0.28
Positioning, not flow
Max pain
17.50
-11.7% from spot
ATM implied vol
84.7%
Nearest strike to spot
Skew (10% OTM)
-7.4%
Calls bid over puts
Call volume
10
Contracts, this expiry
Put volume
3
Contracts, this expiry
Heaviest call OI
22.50
11 contracts
Heaviest put OI
2.50
3 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing
MT Newswires · 3d ago
Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?
Simply Wall St. · 11d ago
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
GlobeNewswire · 16d ago
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
GlobeNewswire · 31d ago
Avalo Therapeutics Says Some Shareholders May Sell Up to 128,189 Shares
MT Newswires · 36d ago
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
GlobeNewswire · 46d ago
Avalo Therapeutics (AVTX) Is Up 12.9% After Broad Russell Index Additions - What's Changed
Simply Wall St. · 54d ago
Sector Update: Healthcare Stocks Mixed Premarket Friday
MT Newswires · 57d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.